09.02.14
Integra LifeSciences Holdings Corporation has made changes to the leadership of its Orthopedics and Tissue Technologies business. The new organization, according to company brass, enables the firm to use its resources more efficiently "in order to better invest in new products and other growth initiatives."
The division, company officials claim, is now structured to "maximize Integra's existing channels, build new ones and launch new products more effectively."
Mark Augusti, president of the Orthopedics and Tissue Technologies division, appointed leaders reporting to him for the following areas: marketing for the division and strategy for Advanced Wound Care, orthopedics product development, quality and regulatory, U.S. extremities sales, and U.S. spine and orthobiologic sales.
"This new combined organization will allow us to deploy our best people across our product development teams, enable common approaches in areas such as marketing, product launches, sourcing and kitting, and provide new organic growth opportunities," said Augusti.
"After 11 years of running Integra Spine's product development efforts, I am excited to work with Mark on integrating and enhancing our product development efforts across orthopedic hardware," said Colin Smith, vice president, Global Hardware Product Development. "We have an opportunity within our pipeline to develop products that allow our sales force to better address the needs of their surgeons with differentiated technology platforms."
"While the combination simplifies and streamlines the structure internally, we remain committed to our dedicated and distinct selling organizations for extremities and spine to best reach our customers," Augusti added.
Over the near term, expense reductions from the new organization will be invested in growth, including new product development and sales efforts in advanced wound care, extremities and spine, officials said. As a result, the company is not making any changes to its financial guidance for 2014.
Plainsboro, N.J.-based Integra makes products for orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery.
The division, company officials claim, is now structured to "maximize Integra's existing channels, build new ones and launch new products more effectively."
Mark Augusti, president of the Orthopedics and Tissue Technologies division, appointed leaders reporting to him for the following areas: marketing for the division and strategy for Advanced Wound Care, orthopedics product development, quality and regulatory, U.S. extremities sales, and U.S. spine and orthobiologic sales.
"This new combined organization will allow us to deploy our best people across our product development teams, enable common approaches in areas such as marketing, product launches, sourcing and kitting, and provide new organic growth opportunities," said Augusti.
"After 11 years of running Integra Spine's product development efforts, I am excited to work with Mark on integrating and enhancing our product development efforts across orthopedic hardware," said Colin Smith, vice president, Global Hardware Product Development. "We have an opportunity within our pipeline to develop products that allow our sales force to better address the needs of their surgeons with differentiated technology platforms."
"While the combination simplifies and streamlines the structure internally, we remain committed to our dedicated and distinct selling organizations for extremities and spine to best reach our customers," Augusti added.
Over the near term, expense reductions from the new organization will be invested in growth, including new product development and sales efforts in advanced wound care, extremities and spine, officials said. As a result, the company is not making any changes to its financial guidance for 2014.
Plainsboro, N.J.-based Integra makes products for orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery.